20.500.12556/DiRROS-12422
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
non-small cell lung carcinoma
drug therapy
KEYNOTE-024 trial
pemrolizumab
treatment
nedrobnocelični karcinom pljuč
terapija z zdravili
raziskava KEYNOTE-024
pemrolizumab
zdravljenje
true
false
true
Elsevier
Angleški jezik
Ni določen
© 2019 THE AUTHORS
Neznano
2020-09-21 11:57:10
2020-09-21 11:57:10
2022-08-18 03:37:20
0000-00-00 00:00:00
2019
0
Velika Britanija
0
Nasl. z nasl. zaslona;
Soavtorica iz Slovenije: T. Cufer;
Opis vira z dne 15. 1. 2020;
str. 1686-1688
iss. 11
Vol. 30
Nov. 2019
0000-00-00
Zaloznikova
Objavljeno
NiDoloceno
0000-00-00
0000-00-00
0000-00-00
616.2
1569-8041
10.1093/annonc/mdz295
2048615281
3151892
RAZ_Mountzios_Giannis_i2019.pdf
RAZ_Mountzios_Giannis_i2019.pdf
1
0E9697A221FB531E45F7409FE050F7AE
1bdad3a66871089a7fe89fd345d65ffafe674986494eef32f26e030469f62480
8d8fc2b0-17b6-11ed-b6b8-001a4af901a5
https://dirros.openscience.si/Dokument.php?lang=slv&id=17307
https://academic.oup.com/annonc/article-abstract/30/11/1686/5559466?redirectedFrom=fulltext
1
https://dirros.openscience.si/Dokument.php?lang=slv&id=14984
Univerzitetna klinika za pljučne bolezni in alergijo Golnik
0
0
0